Concepedia

Amy Barone

AB

Statistics

Publications

11

Citations

551

H-Index

10

Active since

2013

Affiliations

Center for Drug Evaluation and Research(Current)

United States Food and Drug Administration

Washington University in St. Louis

The University of Texas MD Anderson Cancer Center

Mallinckrodt (United States)

Amy Barone is an author at Center for Drug Evaluation and Research specializing in medicine, oncology, and brain tumors.

ORCID

Publications per year

2013–2025

11

Publications

11

Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis

Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey et al. · The Lancet Oncology · 2018 · 177 citations · Full text

, , +17

FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen

Amy Barone, Dow-Chung Chi, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 88 citations · Full text

, , +16

FDA Approval Summary: Pembrolizumab for the Treatment of Patients with Unresectable or Metastatic Melanoma

Amy Barone, Maitreyee Hazarika, Marc R. Theoret et al. · Clinical Cancer Research · 2017 · 87 citations

, , +12

FDA Approval Summary: Cabozantinib for Differentiated Thyroid Cancer

Elizabeth S. Duke, Amy Barone, Somak Chatterjee et al. · Clinical Cancer Research · 2022 · 47 citations · Full text

, , +16

Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma

Amy Barone, Rajarshi Sengupta, Nicole M. Warrington et al. · Oncotarget · 2014 · 41 citations · Full text

, , +17

1–5 of 11